These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25597703)

  • 1. Flicker electroretinograms before and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion.
    Yasuda S; Kachi S; Ueno S; Piao CH; Terasaki H
    Acta Ophthalmol; 2015 Sep; 93(6):e465-8. PubMed ID: 25597703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
    Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
    BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2019 Aug; 139(1):67-74. PubMed ID: 30980231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supernormal Flicker ERGs in Eyes With Central Retinal Vein Occlusion: Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent.
    Miyata R; Kondo M; Kato K; Sugimoto M; Matsubara H; Ikesugi K; Ueno S; Yasuda S; Terasaki H
    Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5854-5861. PubMed ID: 30550616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
    Yasuda S; Kachi S; Ueno S; Ushida H; Piao CH; Kondo M; Terasaki H
    Jpn J Ophthalmol; 2014 May; 58(3):232-6. PubMed ID: 24668132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
    Fan C; Wang Y; Ji Q; Zhao B; Xie J
    Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    Retina; 2016 Sep; 36(9):1726-32. PubMed ID: 26866527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of focal macular and full-field electroretinograms after intravitreal aflibercept in patients with central retinal vein occlusion.
    Nishimura T; Machida S; Hara Y
    Doc Ophthalmol; 2020 Oct; 141(2):169-179. PubMed ID: 32215778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
    Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
    Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
    Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial.
    Kreutzer TC; Wolf A; Dirisamer M; Strauss RW; Foerster P; Feltgen N; Pielen A; Hattenbach LO; Kampik A; Priglinger SG
    Ophthalmologica; 2015; 233(1):8-17. PubMed ID: 25502833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.